Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone

Sponsor
Montreal Heart Institute
Study ID
NCT07257198
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Myocardial Infarction
  • NSTEMI - Non-ST Segment Elevation MI
  • STEMI (ST Elevation MI)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ticagrelor + placebo — DRUG
    Ticagrelor 90 mg twice daily + placebo once daily
  • Ticagrelor + aspirin — DRUG
    Ticagrelor 90 mg twice daily + aspirin 80 mg once daily

Study Details

In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.

Key Dates

First listed
Dec 2, 2025
Start date
Mar 3, 2026
Status verified
Mar 2026
Primary completion
Jan 1, 2030
Completion
Jan 1, 2031

Study Design

Enrollment
2,570 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ticagrelor monotherapy
    Ticagrelor 90 mg orally twice daily + placebo orally once daily
  • Active Comparator: DAPT with ticagrelor and aspirin
    Ticagrelor 90 mg orally twice daily + aspirin 80 mg orally once daily

Primary Outcome Measure

Bleeding [ Time Frame: From randomization to 12 months ]

Central Contacts

Related Studies